申请人:Yoshitomi Pharmaceutical Industries, Ltd.
公开号:US04618607A1
公开(公告)日:1986-10-21
1,4-Dihydropyridine-3,5-dicarboxylic acid ester derivatives of the general formula: ##STR1## or acid addition salts thereof, wherein W is --CH.dbd. or --N.dbd.; Y is --CH.dbd.CH--, --O--, --S--, --CH.dbd.N(O)p-- (p is zero or 1) or --N(R)-- (R is hydrogen or lower alkyl); X.sup.1, X.sup.2 and X.sup.3 are the same or different, and are each hydrogen, halogen, nitro, trifluoromethyl, cyano or lower alkylthio; Z is aryl or 5- or 6-membered aromatic heterocyclic ring (which may have a substituent or two or three substituents which may be the same or different, and the substituent may be halogen, lower alkyl, lower alkoxy, lower alkanoylamino, cyano, nitro, lower alkylthio, trifluoromethyl, sulfamoyl, di-lower alkylsulfamoyl, amino or di-lower alkylamino); ##STR2## is 5- to 7-membered heterocyclic ring which may have nitrogen atom, oxygen atom, sulfur atom or unsaturated bond on the ring, and may be substituted by lower alkyl, lower alkoxycarbonyl, lower alkanoylamino, ethylenedioxy or --(CH.sub.2).sub.m --OR.sup.4 (R.sup.4 is hydrogen, lower alkyl or lower alkanoyl and m is 0, 1 or 2); R.sup.1 and R.sup.2 are the same or different, and are each lower alkyl; R.sup.3 is lower alkyl, aralkyl, heteroaralkyl; and n is an integer 1 to 5. Such compounds are useful as antihypertensive agents and as therapeutic agents for cardiac and cerebral circulation disorders.
1,4-二氢吡啶-3,5-二羧酸酯衍生物的一般式:##STR1##或其酸盐,其中W为--CH.dbd.或--N.dbd.;Y为--CH.dbd.CH--,--O--,--S--,--CH.dbd.N(O)p--(p为零或1)或--N(R)--(R为氢或低碳基);X^1,X^2和X^3相同或不同,分别为氢,卤素,硝基,三氟甲基,氰基或低硫代烷基;Z为芳基或5-或6-成员芳香杂环(可能有一个取代基或两个或三个取代基,取代基可能相同或不同,取代基可以是卤素,低碳基,低烷氧基,低烷酰氨基,氰基,硝基,低硫代烷基,三氟甲基,磺胺基,二低烷基磺胺基,氨基或二低烷基氨基);##STR2##为5-至7-成员杂环,可能在环上有氮原子,氧原子,硫原子或不饱和键,并且可能被低烷基,低烷氧羰基,低烷酰氨基,乙二氧基或--(CH.sub.2).sub.m --OR.sup.4(R.sup.4为氢,低烷基或低烷酰基,m为0, 1或2)取代;R^1和R^2相同或不同,分别为低烷基;R^3为低烷基,芳基烷基,杂芳基烷基;n为1到5的整数。这些化合物可用作降压药物和治疗心脏和脑循环障碍的药物。